Summary
Glycosaminoglycans (GAGs) are potent inhibitors of calcium oxalate growth and aggregation. The synthetic GAG pentosan polysulphate (PPS) was used in the treatment of patients with renal calcium stone disease. Altogether, 121 patients were included in an open trial over a 3-year-period. The average stone episode rate and the stone operation rate were no different during treatment and in the pretreatment period. Altogether 48% of the patients were entirely stone-free during follow-up, whereas 29/56 patients who continued to form stones reported smaller stones that were more easily passed. It is concluded that there may be a role for PPS in the treatment of recurrent renal calcium stone disease, but a controlled study may be needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Danielson BG, Fellström B, Wikström B (1989) Glycosaminoglycans as inhibitors of renal stone formation. In: Walker VR, Sutton RAL, Cameron ECB, Pak CYC, Robertson WG (eds) Urolithiasis. Plenum, New York, pp 101–104
Fellström B, Björklund U, Danielson BG, Eriksson H, Odlind B, Tengblad A (1986) Pentosan polysulphate (Elmiron): pharmacokinetics and effects on the urinary inhibition of crystal growth. Fortschr Urol Nephrol 25:340–344
Fellström B, Danielson BG, Ljunghall S, Wikström B (1986) Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta 158:229–235
Fellström B, Lindsjö M, Danielson BG, Karlsson FA, Ljunghall S (1989) Binding of glycosaminoglycan inhibitors to calcium oxalate crystals in relation to ionic strength. Clin Chim Acta 180:213–220
Fleisch H (1978) Inhibitors and promoters of stone formation. Kidney Int 13:361–371
Robertson WG, Hughes H, Barkworth SA, Walker VR (1988) Competition between the known inhibitors and promoters of calcium oxalate crystallization in urine. In: Martelli A, Buli P, Marchesini B (eds) Inhibitors of crystallization in renal lithiasis and their clinical application. Acta Medica, Bologna
Robertson WG, Knowles F, Peacock M (1976) Urinary acid mucopolysaccharide inhibitors of calcium oxalate crystallisation. In: Fleisch H, Robertson WG, Smith LH, Wahlensieck W (eds) Urolithiasis research. Plenum, New York, pp 331–334
Robertson WG, Peacock M, Marshall RW, Marshall EH, Nordin BEC (1976) Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med 294:249–252
Robertson WG, Peacock M, Nordin BEC (1973) Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43:31–37
Smith LH, Meyer JL, McCall JT (1973) Chemical nature of crystal inhibition isolated from human urine. In: Cifuentes Delatte L, Rapado A, Hodgkinson A (eds) Urinary calculi. Karger, Basel, pp 318–327
Varadi DP, Cifonelli JA, Dorfman A (1967) The acid mucopolysaccharides in normal urine. Biochim Biophys Acta 141:103–117
Wessler E (1971) The nature of the non-ultrafilterable glycosaminoglycans of normal human urine. Biochem J 122:373–384
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fellström, B., Backman, U., Danielson, B. et al. Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate. World J Urol 12, 52–54 (1994). https://doi.org/10.1007/BF00182052
Issue Date:
DOI: https://doi.org/10.1007/BF00182052